SEARCH

SEARCH BY CITATION

References

  • 1
    Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
  • 2
    Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. HEPATOLOGY 2000; 32: 1224-1229.
  • 3
    Hasegawa K, Kokudo N, Imamura H, Matsuyama Y, Aoki T, Minagawa M, et al. Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005; 242: 252-259.
  • 4
    Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Tahara M, Suzuki T, et al. Recurrence patterns after hepatectomy of hepatocellular carcinoma: implication of Milan criteria utilization. Ann Surg Oncol 2009; 16: 1560-1571.
  • 5
    Ikai I, Arii S, Kojiro M, Ichida T, Makuuchi M, Matsuyama Y, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
  • 6
    Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007; 141: 330-339.
  • 7
    Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999; 86: 1032-1038.
  • 8
    Shimada M, Takenaka K, Fujiwara Y, Gion T, Kajiyama K, Maeda T, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma. Cancer 1996; 78: 2094-2100.
  • 9
    Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007; 95: 235-240.
  • 10
    Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002; 6: 224-232; discussion 232.
  • 11
    Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136: 25-30; discussion 31.
  • 12
    Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4: 111-117.
  • 13
    Inoue S, Nakao A, Harada A, Nonami T, Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 1994; 89: 2222-2226.
  • 14
    Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207.
  • 15
    Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375-1382.
  • 16
    Kang P, Madera M JrWRA, Goldman R, Mechref Y, Novotny MV. Glycomic alterations in the highly-abundant and lesser-abundant blood serum protein fractions for patients diagnosed with hepatocellular carcinoma. Int J Mass Spectrom 2011; 305: 185-198.
  • 17
    Vanhooren V, Liu XE, Franceschi C, Gao CF, Libert C, Contreras R, et al. N-glycan profiles as tools in diagnosis of hepatocellular carcinoma and prediction of healthy human ageing. Mech Ageing Dev 2009; 130: 92-97.
  • 18
    Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics 2007; 6: 43-55.
  • 19
    An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, et al. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res 2006; 5: 1626-1635.
  • 20
    Miura Y, Hato M, Shinohara Y, Kuramoto H, Furukawa J, Kurogochi M, et al. BlotGlycoABCTM, an integrated glycoblotting technique for rapid and large scale clinical glycomics. Mol Cell Proteomics 2008; 7: 370-377.
  • 21
    Nishimura S, Niikura K, Kurogochi M, Matsushita T, Fumoto M, Hinou H, et al. High-throughput protein glycomics: combined use of chemoselective glycoblotting and MALDI-TOF/TOF mass spectrometry. Angew Chem Int Ed Engl 2004; 44: 91-96.
  • 22
    Furukawa J, Shinohara Y, Kuramoto H, Miura Y, Shimaoka H, Kurogochi M, et al. Comprehensive approach to structural and functional glycomics based on chemoselective glycoblotting and sequential tag conversion. Anal Chem 2008; 80: 1094-1101.
  • 23
    Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, et al. New Inuyama Classification; new criteria for histlogical assessment of chronic hepatitis. Int Hepatol Commun 1996; 6: 112-119.
  • 24
    The Liver Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 3rd English ed. Tokyo, Japan: Kanehara & Co.
  • 25
    Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control 1974; 19: 716-723.
  • 26
    Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer 1989; 64: 1700-1707.
  • 27
    Hanazaki K, Kajikawa S, Koide N, Adachi W, Amano J. Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 2001; 96: 1243-1250.
    Direct Link:
  • 28
    Matsumoto Y, Suzuki T, Asada I, Ozawa K, Tobe T, Honjo I. Clinical classification of hepatoma in Japan according to serial changes in serum alpha-fetoprotein levels. Cancer 1982; 49: 354-360.
  • 29
    Yang X, Zhang Y, Zhang L, Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett 2008; 271: 281-293.
  • 30
    Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. Exp Biol Med (Maywood) 2001; 226: 377-408.
  • 31
    Smith JB. Occurrence of alpha-fetoprotein in acute viral hepatitis. Int J Cancer 1971; 8: 421-424.
  • 32
    Silver HK, Gold P, Shuster J, Javitt NB, Freedman SO, Finlayson ND. Alpha(1)-fetoprotein in chronic liver disease. N Engl J Med 1974; 291: 506-508.
  • 33
    Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62( Suppl 1): 57-63.
  • 34
    Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, Yokoo H, et al. N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer 2007; 6: 32.
  • 35
    Tang Z, Varghese RS, Bekesova S, Loffredo CA, Hamid MA, Kyselova Z, et al. Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res 2010; 9: 104-112.
  • 36
    Ding N, Nie H, Sun X, Sun W, Qu Y, Liu X, et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing 2011; 40: 568-575.